Behçet's disease - a contemporary review

Journal of Autoimmunity

Volumn 32, Issue 3-4, 2009, Pages 178-188

  Mendes, Daniela ^a   Correia, Margarida ^a   Barbedo, Marta ^a   Vaio, Teresa ^a   Mota, Margarida ^a   Gonçalves, Olga ^a   Valente, João ^a  

^a CENTRO HOSPITALAR DE VILA NOVA DE GAIA ESPINHO   (Portugal)

Author keywords

Beh et's; HLA B51; Oral genital ulcers; Uveitis

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; AZATHIOPRINE; BLOOD CLOTTING FACTOR 5; CHLORAMBUCIL; CHLORHEXIDINE; COLCHICINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DAPSONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ETANERCEPT; HEAT SHOCK PROTEIN 65; HLA B51 ANTIGEN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; METHOTREXATE; METHYLPREDNISOLONE; METHYLPREDNISOLONE ACETATE; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE; RETINA S ANTIGEN; SALAZOSULFAPYRIDINE; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL PAIN; ALOPECIA; ANEURYSM; ANOREXIA; ANTIBODY PRODUCTION; ARTHRITIS; ARTICLE; AUTOIMMUNITY; BEHCET DISEASE; BONE MARROW SUPPRESSION; BUDD CHIARI SYNDROME; CATARACT; CAVA VEIN DISEASE; CEREBRAL SINUS THROMBOSIS; CLINICAL FEATURE; CLINICAL TRIAL; COLITIS; CONTACT DERMATITIS; CUSHINGOID SYNDROME; DEEP VEIN THROMBOSIS; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM ULCER; DISEASE ACTIVITY; DISEASE COURSE; DIZZINESS; DRUG ERUPTION; DRUG TOLERABILITY; ECZEMA; ELECTROLYTE DISTURBANCE; ERYTHEMA NODOSUM; EYE DISEASE; FLU LIKE SYNDROME; FOLLICULITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; GENITAL ULCER; GINGIVA HYPERPLASIA; HEADACHE; HEART DISEASE; HIRSUTISM; HLA TYPING; HUMAN; HYPERTENSION; IMMUNE SYSTEM; INFECTION; INFECTION RESISTANCE; INFERTILITY; INJECTION SITE REACTION; INTRAOCULAR PRESSURE; LABORATORY TEST; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; METASTASIS; MOUTH LESION; MOUTH ULCER; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; OSTEOPOROSIS; PAPULOPUSTULAR SKIN LESION; PARESTHESIA; PATHOGENESIS; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RECURRENT DISEASE; RETINA MACULA EDEMA; RISK FACTOR; SEDATION; SIDE EFFECT; SKIN DEFECT; SKIN ULCER; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION; UVEITIS; VASCULAR DISEASE; VOMITING; WEIGHT GAIN;

AUTOIMMUNITY; BEHCET SYNDROME; CYTOKINES; HEAT-SHOCK PROTEINS; HLA-B ANTIGENS; HUMANS; INTERFERON-ALPHA;

EID: 67349196503     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2009.02.011     Document Type: Article

References (150)

1. Sakane T., Takeno M., Suzuki N., and Inaba G. Behçet's disease. N Engl J Med 341 (1999) 1284-1291
2. Yurdakul S., Hamuryudan V., and Yazici H. Behçet's syndrome. Curr Opin Rheumatol 16 (2003) 38-42
3. Evereklioglu C. Current concepts in the etiology and treatment of Behçets disease. Surv Ophthalmol 50 (2005) 297-350
4. Sut N., Seyahi E., Yurdakul S., Senocak M., and Yazici H. A cost analysis of Behçet's syndrome in Turkey. Rheumatology 46 (2007) 678-682
5. Feigenbaum A. Description of Behçet's syndrome in the Hippocratic third book of endemic diseases. Br J Ophthalmol 40 (1956) 355-357
6. Evereklioglu C. The migration pattern, patient selection with diagnostic methodological flaw and confusing naming dilemma in Behçet disease. Eur J Echocardiogr 8 (2007) 167-173
7. Zouboulis C.C. Benediktos Adamantiades and his forgotten contributions to medicine. Eur J Dermatol 12 (2002) 471-474
8. Behçet H. Über rezidivierende, aphthöse, durch ein virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 105 (1937) 1152-1157
9. Behçet H. Considerations sur les lesions aphteuses de la bouche et des parties genitals, ainsi que sur les manifestations oculaires d'origine probablement virutique et observations concernant leur foyer d'infection. Bull Soc Fr Dermatol Syphiligr 45 (1938) 420-433
10. Behçet H. Einige Bemerkungen zu meinen Beobachtungen über den Tri-Symptomenkomplex. Med Welt 35 (1939) 1222-1227
11. Behçet H. Some observations on the clinical picture of the so-called triple symptom complex. Dermatologica 81 (1940) 73-83
12. Erdemir A.D., and Öncel O. Prof. Dr. Hulusi Behcet (a famous Turkish physician) (1889-1948) and Behcet's disease from the point of view of the history of medicine and some results. J Intl Soc Hist Islamic Med 5 (2006) 51-63
13. Zouboulis C.C., and Kakdamanis P. Early descriptions of Adamantiades-Behçet's disease. Ann Rheum Dis 62 (2003) 691-692
14. Cheng T.O. Some historical notes on Behçet's disease. Chest 119 (2001) 667-668
15. Tirilomis T. Some more historical notes on Adamantiades-Behçet's disease. Chest 120 (2001) 2115-2116
16. Verity D.H., Marr J.E., Ohno S., Wallace G.R., and Stansford M.R. Behçet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 54 (1999) 213-220
17. Zouboulis C.C. Epidemiology of Adamantiades-Behçet's disease. Ann Med Interne 150 (1999) 488-498
18. Azizlerli G., Kose A.A., Sarica R., Gul A., Tutkun I.T., Kulaç M., et al. Prevalence of Behçet's disease in Istanbul, Turkey. Int J Dermatol 42 (2003) 803-806
19. Zouboulis C.C., Kotter I., Djawari D., Kirch W., Kohl P.K., Ochsendorf F.R., et al. Epidemiological features of Adamantiades-Behcet's disease in Germany and in Europe. Yonsei Med J 38 (1997) 411-422
20. Tugal-Tutkun I., Onal S., Altan-Yaycioglu R., Huseyin Altunbas H., and Urgancioglu M. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol 138 (2004) 373-380
21. Tursen U., Gurler A., and Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behcet's disease. Int J Dermatol 42 (2003) 346-351
22. Oshima Y., Shimizu T., Yokohari R., Matsumoto T., Kano K., Kagami T., et al. Clinical studies on Behçet's syndrome. Ann Rheum Dis 22 (1963) 36-45
23. Yazici H., Tüzün Y., Pazarli H., Yurdakul S., Ozyazgan Y., Ozdaǧan H., et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 43 (1984) 783-789
24. Tsai J., Chen G.-S., Lu Y.-W., Wu C.S., and Lan C.C. Late-onset Behçet's disease does not correlate with indolent clinical course: report of seven Taiwanese patients. J Eur Acad Dermatol Venereol 22 (2008) 596-600
25. Saricaoglu H., Karadogan K.S., Bayzazit N., Yucel A., Dilek K., and Tunali S. Clinical features of late-onset Behçet's disease: report of nine cases. Int J Dermatol 45 (2006) 1284-1287
26. Gül A., Inanç M., Öcal L., Aral L., and Koniçe M. Familial aggregation of Behçet's disease in Turkey. Ann Rheum Dis 59 (2000) 622-625
27. Koné-Paut I., Yurdakul S., Bahabri S.A., Shafae N., Ozen S., Ozdogan H., et al. Clinical features of Behçet's disease in children: an international collaborative study of 86 cases. J Pediatr 132 (1998) 721-725
28. Guillaume-Czitrom S., Berger C., Pajot C., Bodaghi B., Wechsler B., and Kone-Paut I. Efficacy and safety of interferon-α in the treatment of corticodependent uveitis of paediatric Behcet's disease. Rheumatology 46 (2007) 1570-1573
29. Uzun S., Alpsoy E., Durdu M., and Akman A. The clinical course of Behcet's disease in pregnancy: a retrospective analysis and review of the literature. J Dermatol 30 (2003) 499-502
30. Bang D, Chun YS, Haam IB, Lee ES, Lee S, et al. The influence of pregnancy on Behcet's disease. Yonsei Med J 1997;38:437-443.
31. Pay S., Şimşek I., Erdem H., and Dinç A. Immunopathogenesis of Behçet's disease with special emphasize to the possible role of antigen presenting cells. Rheumatol Int 27 (2007) 417-424
32. Kulaber A., Tugal-Tutkun I., Sibel P., Akman-Demir G., Kaneko F., Gül A., et al. Pro-inflammatory cellular immune response in Behçet's disease. Rheumatol Int 27 (2007) 1113-1118
33. Ahmad T., Wallace G.R., James T., Neville M., Bunce M., Mulcahy-Hawes K., et al. Mapping the HLA association in Behçet's disease a role for tumor necrosis factor polymorphisms?. Arthritis Rheum 48 (2003) 807-813
34. Marshall S. Behçet's disease. Best Pract Res Clin Rheumatol 18 (2004) 291-311
35. Coskun M., Bacanli A., Sallakci N., Alpsoy E., Yavuzer U., and Yegin O. Specific interleukin-1 gene polymorphisms in Turkish patients with Behçet's disease. Exp Dermatol 14 (2005) 124-129
36. Karasneh J., Hajeer A.H., Barrett J., Oliver W.E., Thornhill M., and Gül A. Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behçet's disease. Rheumatology 42 (2003) 860-864
37. Boiardi L., Salvarani C., Casali B., Olivieri I., Ciancio G., Cantini F., et al. Intercellular adhesion molecule-1 gene polymorphisms in Behçet's disease. J Rheumatol 28 (2001) 1283-1287
38. Verity D.H., Vaughan R.W., Kondeatis E., Madanat W., Zureikat H., Fayyard F., et al. Intercellular adhesion molecule-1 gene polymorphism in Behçet's disease. Eur J Immunogenet 27 (2000) 73-76
39. Salvarani C., Boiardi L., Casali B., Olivieri I., Ciancio G., Cantini F., et al. Endothelial nitric oxide synthase gene polymorphisms in Behçet's disease. J Rheumatol 29 (2002) 535-540
40. Ayesh S., Abu-Rmaileh H., Nassar S., Al-Shareef W., Abu-Libdeh B., Muhanna A., et al. Molecular analysis of MEFV gene mutations among Palestinian patients with Behçet's disease. Scand J Rheumatol 37 (2008) 370-374
41. Rabinovich E., Shinar Y., Leiba M., Ehrenfeld M., Langewitz P., and Livneh A. Common FMF alleles may predispose to development of Behçet's disease with increased risk for venous thrombosis. Scand J Rheumatol 36 (2007) 48-52
42. Imirzalioglu N., Dursun A., Tastan B., Soysal Y., and Yakicier M.C. MEFV gene is a probable susceptibility gene for Behçet's disease. Scand J Rheumatol 34 (2005) 56-58
43. Lehner T. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease. Int Rev Immunol 14 (1997) 21-32
44. Direskeneli H. Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 60 (2001) 996-1002
45. Ergun T., İnce U., Ekşioǧlu-Demiralp E., Direskeneli H., Gürbüz O., Gürses L., et al. HSP 60 expression in mucocutaneous lesions of Behçet's disease. J Am Acad Dermatol 45 (2001) 904-909
46. Musabak U., Pay S., Erdem H., Simsek I., Pekel A., Dinc A., et al. Serum interleukin-18 levels in patients with Behçet's disease. Is its expression associated with disease activity or clinical presentations?. Rheumatol Int 26 (2006) 545-550
47. Hamzaoui K., Hamzaoui A., Ghorbel I., Khanfir M., and Houman H. Levels of IL-15 in serum and cerebrospinal fluid of patients with Behçet's disease. Scand J Rheumatol 64 (2006) 655-660
48. Houman H., Hamzaoui A., Ghorbel I., Ghorbal I., Khanfir M., Feki M., et al. Abnormal expression of chemokine receptors in Behçet's disease: relationship to intracellular Th1/Th2 cytokines and to clinical manifestations. J Autoimmun 23 (2004) 267-273
49. Bank I., Duvdevani M., and Livneh A. Expansion of γδ T-cells in Behcet's disease: role of disease activity and microbial flora in oral ulcers. J Lab Clin Med 141 (2003) 33-40
50. Verjans G.M., van Hagen P.M., van der Kooi A., Osterhaus A.D., and Baarsma G.S. Vγ9Vδ2 T cells recovered from eyes of patients with Behcet's disease recognize non-peptide prenyl pyrophosphate antigens. J Neuroimmunol 130 (2002) 46-54
51. Hasan A., Fortune F., Wilson A., Warr K., Shinnick T., Mizushima Y., et al. Role of γδ T cells in pathogenesis and diagnosis of Behçet's disease. Lancet 347 (1996) 789-794
52. Frassanito M.A., Dammacco R., Cafforio P., and Dammacco F. Th1 polarization of the immune response in Behcet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 42 (1999) 1967-1974
53. Verity D.H., Wallace G.R., Vaughan R.W., and Stanford M.R. Behçet's disease - from Hippocrates to the third millennium. Br J Ophthalmol 87 (2003) 1175-1183
54. Zierhut M., Mizuki N., Ohno S., Inoko H., Gül A., Onoé K., et al. Immunology and functional genomics of Behçet's disease. Cell Mol Life Sci 60 (2003) 1903-1922
55. Alpsoy E., Zouboulis C.C., and Ehrlich G.E. Mucocutaneous lesions of Behçet's disease. Yonsei Med J 48 (2007) 573-585
56. Alpsoy E., Dönmez L., Bacanli{dotless} A., Apaydin C., Butun B., et al. Review of the chronology of clinical manifestations in 60 patients with Behçet's disease. Dermatology 2007 (2003) 354-356
57. Bang D., Hur W., Lee E.S., and Lee S. Prognosis and clinical relevance of recurrent oral ulceration in Behcet's disease. J Dermatol 22 (1995) 926-929
58. Main D.M.G., and Chamberlain M.A. Clinical differentiation of oral ulceration in Behçet's. Br J Rheumatol 31 (1992) 767-770
59. Nobuyoshi K., Miyazaki A., Iwata D., Ohno S., Stansford M.R., and Chams H. Ocular features of Behçet's disease: an international collaborative study. Br J Ophthalmol 91 (2007) 1579-1582
60. Kump L.I., Moeller K.L., Reed G.F., Kurup S.K., Nussenblatt R.B., and Levy-Clarke G.A. Behçet's disease: comparing 3 decades of treatment response at the National Eye Institute. Can J Ophthalmol 43 (2008) 468-472
61. Ando K., Fujino Y., Hijikata K., Izawa Y., and Masuda K. Epidemiological features and visual prognosis of Behçet's disease. Jpn J Ophthalmol 43 (1999) 312-317
62. Yoshida A., Kawashima H., Motoyama Y., Shibui H., Kaburaki T., Shimizu K., et al. Comparison of patients with Behçet's disease in the 1980s and 1990s. Ophthalmology 111 (2004) 810-815
63. Elgin U., Berker N., and Batman A. Incidence of secondary glaucoma in Behçet disease. J Glaucoma 13 (2004) 441-444
64. Jorizzo J.L., Abernethy J.L., White W.L., Mangelsdorf H.C., Zouboulis C.C., Sarica R., et al. Mucocutaneous criteria for the diagnosis of Behçet's disease: an analysis of clinicopathologic data. J Am Acad Dermatol 32 (1995) 968-976
65. Alpsoy E., Uzun S., Akman A., Acar M.A., Memişoglu H.R., and Başaran E. Histological and immunofluorescence findings of non-follicular papulopustular lesions in patients with Behcet's disease. J Eur Acad Dermatol Venereol 17 (2003) 521-524
66. Akman-Demir G., Serdaroglu P., Tasçi B., and Neuro-Behçet Study Group. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. Brain 122 (1999) 2171-2181
67. Pearce J.M.S. Neurological symptoms of Adamantiades-Behçet's syndrome. J Neurol Neurosurg Psychiatry 77 (2006) 956-957
68. Benamour S., Naji T., Alaoui F.Z., El-Kabli H., and El-Aidouni S. Neurological involvement in Behcet's disease. 154 cases from a cohort of 925 patients and review of the literature. Rev Neurol 162 (2006) 1084-1090
69. Gürler A., Boyvat A., and Türsen U. Clinical manifestations of Behcet's disease: an analysis of 2147 patients. Yonsei Med J 38 (1997) 423-427
70. Atzeni F., Sarzi-Puttini P., Doria A., Boiardi L., Papitone N., and Salvarani C. Behçet's disease and cardiovascular involvement. Lupus 14 (2005) 723-726
71. Gerçek Aktas E., Kaplan M., and Özveren M.F. Basilar artery aneurysm associated with Behçet's disease: a case report. Turk Neurosurg 18 (2008) 35-38
72. Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behçet syndrome A 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003;82:60-76.
73. Ghorbel I.B., Ennaifer R., Lamloum M., Khanfir M., Miled M., and Houman M.H. Budd-Chiari syndrome associated with Behçet's disease. Gastroenterol Clin Biol 32 (2008) 316-320
74. Hamuryudan V., Er T., Seyahi E., Akman C., Tüzün H., Fresko I., et al. Pulmonary artery aneurisms in Behçet's syndrome. Am J Med 117 (2004) 867-870
75. Hamuryudan V., Yurdakul S., Moral F., Numan F., Tüzün H., Tüzüner N., et al. Pulmonary arterial aneurysms in Behçet's syndrome: a report of 24 cases. Br J Rheumatol 33 (1994) 48-51
76. Gurgun C., Ercan E., Ceyhan C., Yavuzgil O., Zoghi M., Aksu K., et al. Cardiovascular involvement in Behcet's disease. Jpn Heart J 43 (2002) 389-398
77. Yurdakul S., Tuzuner N., Yurdakul I., Hamuryudan V., and Yazici H. Gastrointestinal involvement in Behcet's syndrome: a controlled study. Ann Rheum Dis 55 (1996) 208-210
78. Hassard P.V., Binder S.W., Nelson V., and Vasiliauskas E.A. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology 120 (2001) 995-999
79. Badi M.A.A., Zyani M., Kaddouri S., Niamane R., Hda A., and Algayres J.P. Les manifestations articulaires de la maladie de Behçet. À propos de 79 cas. Rev Med Interne 29 (2007) 277-282
80. Fresco I., Yazi{dotless}ci{dotless} H., Bayramiçli M., Yurdakul S., and Mat C. Effect of surgical clearing of the skin on the pathergy phenomenon in Behçet's syndrome. Ann Rheum Dis 52 (1993) 619-620
81. Mason R.M., and Barnes C.G. Behçet's syndrome with arthritis. Ann Rheum Dis 28 (1969) 73-78
82. Mizushima Y. Recent research into Behçet's disease in Japan. Int J Tissue React 10 (1988) 59-65
83. Suzuki K., and Suzuki N. Behçet disease. Clin Exp Med 3 (2004) 10-20
84. O'Duffy J.D. Critères proposes pour la diagnostic maladie Behçet et notes thérapeutiques. Rev Med Interne 36 (1974) 2371-2379
85. Rigby A.S., Chamberlain M.A., and Bhakta B. Behçet's disease. Baillieres Clin Rheumatol 9 (1995) 375-395
86. Dilsen N., Konice M., and Aral O. Our diagnostic criteria for Behçet's disease-an overview. Int Congr Ser 103 (1986) 177-180
87. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 335 (1990) 1078-1080
88. Russell A.I., Lawson W.A., and Haskard D.O. Potential new therapeutic options in Behcet's syndrome. BioDrugs 15 (2001) 25-35
89. Gul A. Standard and novel therapeutic approaches to Behçet's disease. Drugs 67 (2007) 2013-2022
90. Hatemi G., Silman A., Bang D., Bodaghi B., Chamberlain A.M., Gul A., et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 67 (2008) 1656-1662
91. Okada A.A. Drug therapy in Behcet's disease. Ocul Immunol Inflamm 8 (2000) 85-91
92. UpToDate 16.3 Prednisolone Drug Information. Available at:. Accessed November 18, 2008
93. Mat C., Yurdakul S., Uysal S., Gogus F., Ozyazgan Y., Uysal O., et al. A double-blind trial of depot corticosteroids in Behçet's syndrome. Rheumatology 45 (2006) 348-352
94. Yurdakul S., Mat C., Tuzun Y., Ozyazgan Y., Hamuryudan V., Uysal O., et al. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 44 (2001) 2686-2692
95. UpToDate 16.3 Colchicine Drug Information. Available at:. Accessed November 18, 2008
96. Mudun A.B., Ergen A., Ipcioglu S., Burumcek E.Y., Durlu Y., and Arslan M.O. Short-term chlorambucil for refractory uveitis in Behçet's disease. Ocul Immunol Inflamm 9 (2001) 219-229
97. Hirohata S., Suda H., and Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behçet's disease. J Neurol Sci 159 (1998) 181-185
98. Yatscoff R.W., and Aspleslet L.J. The monitoring of immunosuppressive drugs: a pharmacodynamic approach. Ther Drug Monit 20 (1998) 459-463
99. Yazici H., Pazarli H., Barnes C.G., Tüzün Y., Ozyazgan Y., Silman A., et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 322 (1990) 281-285
100. Hamuryudan V.M., Yilmaz O., Hizli N., Mat C., Yurdakul S., Tüzün Y., et al. Azathioprine in Behçet's syndrome effects on long-term prognosis. Arthritis Rheum 40 (1997) 769-774
101. UpToDate 16.3 Azathioprine Drug Information. Available at:. Accessed on November 18, 2008
102. Shek L.P.C., and Lim D.L.C. Thalidomide in Behçet's disease. Biomed Pharmacother 56 (2002) 31-35
103. Hamuryudan V., Mat C., Saip S., Ozyazgan Y., Siva A., Yurdakul S., et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet's Syndrome. Ann Intern Med 128 (1998) 443-450
104. UpToDate 16.3 Thalidomide Drug Information. Available at:. Accessed on November 18, 2008
105. UpToDate 16.3 Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease. Available at:. Accessed November 18, 2008
106. Sharquie K.E., Najim R.A., and Abu-Raghif A.R. Dapsone in Behçet's disease: a double-blind, placebo-controlled, crossover study. J Dermatol 29 (2002) 267-279
107. Yasui K., Ohta K., Kobayashi M., Aizawa T., and Komiyama A. Successful treatment of Behcet's disease with pentoxifylline. Ann Intern Med 124 (1996) 891-893
108. Treusch M., Vonthein R., Baur M., Günayadin I., Koch S., Stübiger N., et al. Influence of human recombinant interferon-α2a (rhIFN- α2a) on altered lymphocyte subpopulations and monocytes in Behçet's disease. Rheumatology 43 (2004) 1275-1282
109. Pipitone N., Olivieri I., Cantini F., Triolo G., and Salvarani C. New approaches in the treatment of Adamantiades-Behcet's disease. Curr Opin Rheumatol 18 (2006) 3-9
110. Kötter I., Zierhut M., Eckstein A.K., Vonthein R., Ness T., Günaydin I., et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior uveitis. Br J Ophthalmol 87 (2003) 423-431
111. Alpsoy E., Durusoy C., Yilmaz E., Ozgurel Y., Ermis O., Yazar S., et al. Interferon alfa-2a in the treatment of Behçet disease a randomized placebo-controlled and double-blind Study. Arch Dermatol 138 (2002) 467-471
112. Nichols J., Ince A., Akduman L., and Mann E. Interferon alfa-2a treatment of neuro-Behçet disease. J Neuroophthalmol 21 (2001) 109-111
113. Aoki T., Tanaka T., Akifuji Y., Ueki J., Nakamura I., Nemoto R., et al. Beneficial effects of interferon-alpha in a case with Behcet disease. Intern Med 39 (2000) 667-669
114. Zouboulis C.C., and Orfanos C.E. Treatment of Adamantiades-Behçet's disease with systemic interferon alfa. Arch Dermatol 134 (1998) 1010-1016
115. Wechsler B., Bodaghi B., Huong D.L.T., Fardeau C., Amoura Z., Cassoux N., et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm 8 (2000) 293-301
116. Georgiou S., Monastirli A., Pasmatzi E., Gartaganis S., Goerz G., and Tsambaos D. Efficacy and safety of systemic recombinant interferon-alpha in Behcet's disease. J Intern Med 243 (1998) 367-372
117. Çalgüneri M., Öztürk M.A., Ertenli I., Hiraz S., Apraç S., and Ozbalkan Z. Effects of interferon α treatment on the clinical course of refractory Behçet's disease: an open study. Ann Rheum Dis 62 (2003) 492-493
118. Kötter I., Günaydin I., Zierhut M., and Stübiger N. The use of interferon α in Behçet disease: review of the literature. Semin Arthritis Rheum 33 (2004) 320-335
119. Kötter I., Vonthein R., Zierhut M., Eckstein A.K., Ness T., Günaydin I., et al. Differential efficacy of human recombinant interferon-α2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial. Semin Arthritis Rheum 33 (2004) 311-319
120. Bodaghi B., Gendron G., Wechsler B., Terrada C., Cassoux X., Huong du L.T., et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 91 (2007) 335-339
121. Stanford M.R. Behçet's syndrome. Br J Ophthalmol 87 (2003) 381-382
122. Langford C.A. Drug insight: anti-tumor necrosis factor therapies for the vasculitic diseases. Nat Clin Pract Rheumatol 4 (2008) 364-370
123. Tugal-Tutkun I., Mudun A., Urgancioglu M., Kamali S., Kasapoglu E., Inanc M., et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum 52 (2005) 2478-2484
124. Sfikakis P.P. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61 (2002) 51-53
125. Triolo G, Vadalà A, Accardo-Palumbo A, Ferrante A, Ciccia F, Giardina E, et al. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behçet's disease. Ann Rheum Dis 2002;61:560-1.
126. Niccoli L., Nannini C., Benucci M., Chindamo D., Cissarà E., Salvarani C., et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology 46 (2007) 1161-1164
127. Sfikakis P.P., Theodossiadis P.G., Katsiari C.G., Kaklamanis P., and Markomichelakis N.N. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 358 (2001) 295-296
128. Sfikakis P.P., Kaklamanis P.H., Elezoglou A., and Katsilambros N. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 140 (2004) 404-406
129. Gulli S., Arrigo C., Bocchino L., Morgante L., Sangari D., Castagna I., et al. Remission of Behçet's disease with anti-tumour necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord 4 (2003) 19
130. Robertson L.P., and Hickling P. Treatment of recalcitrant orogenital ulcers of Behçet's syndrome with infliximab. Rheumatology 40 (2001) 473-474
131. Saulsbury F.T., and Mann J.A. Treatment with infliximab for a child with Behçet's disease. Arthritis Rheum 49 (2003) 599-600
132. Rozenbaum M., Rosner I., and Portnoy E. Remission of Behçet's syndrome with TNFa blocking treatment. Ann Rheum Dis 61 (2002) 283-284
133. Haugeberg G., Velken M., and Johnsen V. Successful treatment of genital ulcers with infliximab in Behçet's disease. Ann Rheum Dis 63 (2004) 744-745
134. Travis S.P.L., Czajkowski M., McGovern D.P.B., Watson R.G., Bell A.L., et al. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor α antibody. Gut 49 (2001) 725-728
135. Pipitone N., Olivieri I., Padula A., D'angelo S., Nigro A., Zuccoli G., et al. Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature. Arthritis Rheum 59 (2008) 285-290
136. Ribi C., Sztajzel R., Delavelle J., and Chizzolini C. Efficacy of TNF α blockade in cyclophosphamide resistant neuro-Behçet disease. J Neurol Neurosurg Psychiatry 76 (2005) 1733-1735
137. Licata G., Pinto A., Tuttolomondo A., Banco A., Ciccia F., Ferrante A., et al. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome. Ann Rheum Dis 62 (2003) 280-281
138. Baki K., Villiger P.M., Jenni D., Meyer .T., and Beer J.H. Behçet's disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment. Ann Rheum Dis 65 (2006) 1531-1532
139. Ohno S., Nakamura S., Hori S., Shimakawa M., Kawashima H., Mochizuki M., et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 31 (2004) 1362-1368
140. Seyahi E., Hamuryudan V., Hatemi G., Melikoglu M., Celik S., Fresko I., et al. Infliximab in the treatment of hepatic vein thrombosis (Budd-Chiari syndrome) in 3 patients with Behçet's syndrome. Rheumatology 46 (2007) 1213-1214
141. Sfikakis P.P., Markomichelakis N., Alpsoy E., Assaad-Khalil S., Bodaghi B., Gul A., et al. Anti-TNF therapy in the management of Behçet's disease - review and basis for recommendations. Rheumatology 46 (2007) 736-741
142. Curigliano V., Giovinale M., Fonnesu C., Cerguaglia C., Verrecchia E., Turbo S., et al. Efficacy of etanercept in the treatment of a patient with Behçet's disease. Clin Rheumatol 27 (2008) 933-936
143. Melikoglu M., Fresco I., Mat C., Ozyazgan Y., Gogus F., Yurdakul, et al. Short-term trial of etanercept in Behçet's disease: a double-blind, placebo-controlled study. J Rheumatol 32 (2005) 98-105
144. Estrach C., Mpofu S., and Moots R.J. Behçet's syndrome: response to infliximab after failure of etanercept. Rheumatology 41 (2002) 1213-1214
145. Mushtaq B., Saeed T., Situnayake R.D., and Murray P.I. Adalimumab for sight-threatening uveitis in Behcet's disease. Eye 21 (2007) 824-825
146. van Laar J.A.M., Missotten T., van Daele P.L., Jamnitski A., Baarsma G.S., van Hagen P.M., et al. Adalimumab: a new modality for Behçet's disease?. Ann Rheum Dis 66 (2007) 565-566
147. Furst D.E., Keystone E.C., Kirkham B., Kavanaugh A., Fleischmann R., Mease P., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 67 (2008) iii22-iii25
148. Botsios C., Sfriso P., Furlan A., and Punzi L. Resistant Behçet disease responsive to Anakinra. Ann Intern Med 149 (2008) 284-286
149. Phipps P.A., Stanford M.R., Sun J.B., Xiao B.G., Holmgren J., Shinnick T., et al. Prevention of mucosally induced uveitis with a HSP60-derived peptide linked to cholera toxin B subunit. Eur J Immunol 33 (2003) 224-232
150. Stanford M., Whittall T., Bergmeier L.A., Lindblad M., Lundin S., Shinnick T., et al. Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet́s disease. Clin Exp Immunol 137 (2004) 201-208